2nd Quarter - Report

WAXMAN STRATEGIES for MEDICINES360

Firm
Client
Income
$9,000
Expenses
—

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Support for non-profit pharmaceutical manufacturers, S. 2257

LobbyistCovered position, as disclosed
KAHAARI KENYATTA New —
JEREMY SHARP LA,Rep Capps 2001-05 PSM, Sen HELP Comm 2007-10 LD, Sen Dodd 2010 DAS for Leg, HHS, 2011-13 Counselor, HHS, 2013-14 Dep Commissioner for Policy, FDA 2015-17

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 2257 (117th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.